Psoriasis is a chronic immune-mediated disorder that commonly affects adults and children. In recent years, pediatric psoriasis has increased in prevalence and the disease is often associated with various comorbidities and psychological distress. The conventional topical treatments for psoriasis, such as corticosteroids, calcineurin inhibitors, vitamin D analogs, anthralin, and coal tar, are often limited by their side effects, tolerability, and/or efficacy, particularly for use in children and on sensitive and intertriginous areas. Recently, the US Food and Drug Administration approved two new topical non-steroidal agents for treating psoriasis that target different pathogenic pathways than the conventional treatments. Roflumilast is a phosphodiesterase type 4 inhibitor approved for the treatment of plaque psoriasis in patients aged 12 years and older. Tapinarof is a novel aryl hydrocarbon receptor modulator approved for adult psoriasis and currently undergoing studies for pediatric psoriasis. Ongoing efforts are also being made to optimize conventional treatments, for instance, a new foam formulation of halobetasol propionate was recently approved for pediatric psoriasis. Clinical trials of various new drugs targeting one or multiple pathogenic pathways of psoriasis, such as Janus kinase inhibitors, different formulations of phosphodiesterase type 4 inhibitors, and aryl hydrocarbon receptor modulators have also been explored. The recent emergence of novel topical agents provides promising new options for managing pediatric psoriasis with the potential to improve clinical outcomes and quality of life. In this article, we review the mechanism of action, efficacy, and safety profile of novel topical agents and discuss their potential roles in the management of pediatric psoriasis.

牛皮癣是一种慢性免疫介导疾病，通常影响成人和儿童。近年来，小儿牛皮癣的患病率有所增加，并且该疾病往往与各种合并症和心理困扰有关。牛皮癣的常规局部治疗，例如皮质类固醇、钙调神经磷酸酶抑制剂、维生素 D 类似物、蒽林和煤焦油，通常因其副作用、耐受性和/或功效而受到限制，特别是在儿童以及敏感和擦间部位使用时。最近，美国食品和药物管理局批准了两种新的外用非甾体药物用于治疗牛皮癣，其致病途径与传统治疗方法不同。Roflumilast 是一种 4 型磷酸二酯酶抑制剂，被批准用于治疗 12 岁及以上患者的斑块状银屑病。Tapinarof 是一种新型芳烃受体调节剂，已被批准用于成人银屑病，目前正在进行儿童银屑病的研究。我们还在不断努力优化传统治疗方法，例如，一种新的丙酸卤倍他索泡沫制剂最近被批准用于治疗儿科银屑病。还探索了针对银屑病一种或多种致病途径的各种新药的临床试验，例如Janus激酶抑制剂、磷酸二酯酶4型抑制剂的不同剂型和芳烃受体调节剂。最近出现的新型外用药物为治疗小儿牛皮癣提供了有前景的新选择，并有可能改善临床结果和生活质量。在本文中，我们回顾了新型外用药物的作用机制、功效和安全性，并讨论了它们在儿童银屑病治疗中的潜在作用。